EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSPREG00000005126
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPREG00000017169
Gene Symbol: GABRG3
4 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPREG00000008733
Gene Symbol: GABRG3
4 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPREG00000003518
Gene Symbol: GABBR1
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSPREG00000004442
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSPREG00000018116
Gene Symbol: GLP2R
4 Cross references
205 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSPREG00000004647
Gene Symbol: LOC103471211
3 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSPREG00000010287
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSPREG00000020418
Gene Symbol: GRIA1
3 Cross references
250 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSPREG00000017532
Gene Symbol: GRIA1
3 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSPREG00000008420
Gene Symbol: GRIA2
4 Cross references
204 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSPREG00000022050
Gene Symbol: GRIA2
3 Cross references
242 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).